Creating advanced CAR-T cells to fight HIV infection
Advanced generation infection-proof anti-HIV CAR-T with YY1 RNAi to block T cell exhaustion in NHP model
['FUNDING_SBIR_2'] · IT BIO, LLC · NIH-10890687
This study is testing a new kind of CAR-T cell therapy that aims to help people with HIV by creating special immune cells that can better find and destroy HIV-infected cells, and it will first be tried out in monkeys to see how well it works.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | IT BIO, LLC (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10890687 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new type of CAR-T cell therapy specifically designed to target and eliminate HIV-infected cells. By using advanced molecular engineering techniques, the researchers aim to enhance the effectiveness of these CAR-T cells by addressing issues like T cell exhaustion, which can hinder immune responses. The study will involve testing these engineered T cells in non-human primates to evaluate their ability to eradicate HIV. If successful, this approach could lead to new treatment options for individuals living with HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals living with HIV who have not responded well to existing treatments.
Not a fit: Patients who are not infected with HIV or those who have advanced AIDS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option for patients with HIV, potentially leading to long-term remission or eradication of the virus.
How similar studies have performed: While CAR-T cell therapies have shown promise in treating other cancers, this specific approach for HIV is novel and has not been extensively tested in clinical settings.
Where this research is happening
BOSTON, UNITED STATES
- IT BIO, LLC — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JUNGHANS, RICHARD P — IT BIO, LLC
- Study coordinator: JUNGHANS, RICHARD P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus